* Agios Pharmaceuticals Inc reported a quarterly adjusted loss of $1.45 per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-1.47. The mean expectation of nine analysts for the quarter was for a loss of $1.65 per share. Wall Street expected results to range from $-1.78 to $-1.53 per share.
* Revenue rose 46% to $8.19 million from a year ago; analysts expected $8.37 million.
* Agios Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.45.
* The company reported a quarterly loss of $81.55 million.
* Agios Pharmaceuticals Inc shares had risen by 15.1% this quarter and gained 51.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 5.8% in the last three months.
* In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $45.00 This summary was machine generated from LSEG data May 2 at 03:08 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.65 -1.45 Beat
Dec. 31 2023 -1.65 -1.72 Missed
Sep. 30 2023 -1.70 -1.64 Beat
Jun. 30 2023 -1.56 -1.51 Beat
Comments